Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-01-06
1998-10-20
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
058246924
ABSTRACT:
Patients susceptible to or suffering from central nervous system disorders (e.g., neurodegenerative diseases including presenile dementia, senile dementia of the Alzeimer's type, and Parkinsonism including Parkinson's disease) are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and
REFERENCES:
patent: 3870794 (1975-03-01), Hutchinson et al.
patent: 4578394 (1986-03-01), Allen et al.
patent: 4965074 (1990-10-01), Leeson
patent: 5210076 (1993-05-01), Berliner et al.
patent: 5212188 (1993-05-01), Caldwell et al.
patent: 5227391 (1993-07-01), Caldwell et al.
patent: 5242935 (1993-09-01), Lippiello et al.
patent: 5597919 (1997-01-01), Dull et al.
Baron, J., "Cigarette smoking and Parkinson's disease", Neurology, vol. 36, pp. 1490-1496 (1986).
Benwell, M. et al., "Evidence that Tobacco Smoking Increses the Density of Neurochemistry, vol. 50, pp. 1243-1247 (1988).
Clark, P. et al., "Electrophysiological actions of nicotine on substantia nigra single units", Br. J. Pharm., vol. 85, pp. 827-835 (1985).
Decina, P. et al., "Cigarette Smoking and Neuroleptic-Induced Parkinsonism", Biol. Psychiatry, vol. 28, pp. 502-508 (1990).
Giacobini, E., "Pharmacotherapy of Alzheimer's Disease: New Drugs and Novel Strategies", Alzheimer's Disease: Advances in Clinical and Basic Research, S61, pp. 529-538 (1993).
Giacobini, E., "New Cholinesterase Inhibitors for Treatment of Alzheimer's Disease", Alzheimer's Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies, S80, pp. 627-631 (1991).
Giacobini, E., "Cholinergic Receptors in Human Brain: Effects of Aging and Alzheimer's Disease", Journal of Neuroscience Research, vol. 27, pp. 548-560 (1990).
Giacobini, E., "The Second Generation of Cholinesterasse Inhibitors: Pharmacological Aspects", Pharmacological Basis of Cholinergic Therapy of Alz. Dis., Eds., Becker, R. et al. Boxton:Birkhauser (1991).
Giacobini, E. et al., "Toward a Third Generation of Cholinesterase Inhibitors", Pharmacological Basis of Cholinergic Therapy of Alz. Dis., Eds., Becker, R. et al., Boxton:Birkhauser (1991).
Hall, G. et al., "Effects of Nicotine on the Release of .sup.3 H-Noradrenaline from the Hypothalamus", Biochemical Pharmacology, vol. 21, pp. 1829-1838 (1972).
Harsing, L. et al., "Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autoreceptor Desensitization", Journal of Neurochemistry, vol. 59, pp. 48-54 (1993).
Hery, F. et al., "Control of the Release of Newly Synthetized .sup.3 H-5-Hydroxytryptamine by Nicotinic and Muscarinic Receptors in Rat hypothalamic Slices", Arch. Int. Pharmacodyn. Ther., vol. 296, pp. 91-97 (1977).
Janson, A. et al., "Protective effects of chronic nicotine treatment on lesioned nigrostriatal dop neurons in the male rat", Progress in Brain Research, vol. 79, pp. 257-265 (1989).
Jarvik, M. "Beneficial effects of nicotine", British Journal of Addition, vol. 86, pp. 571-575 (1991).
Jones, A. et al., "Alzheimer's Disease: Clinical and Pathological Characteristics", Intern. J. Neuroscience, vol. 50, pp. 147-168 (1990).
Marks, M. et al., "Effects on Chronic Nicotine Infusion on Tolerance Development and Nicotinic Receptors", The Journal of Pharmacology and Experimental Therapeutics, vol. 226, pp. 817-825 (1983).
Hughes, "Proceedings from Intl. Symp. Nic.", S40 (1994).
Newhouse, P. et al., "Intravenous nicotine in Alzheimer's disease: a pilot study", Psychopharmacology, vol. 95, pp. 171-175 (1988).
Nordberg, A. et al., "The role of nicotinic receptors in the pathophysiology of Alzheimer's disease", Progress in Brain Research, vol. 79, pp. 353-362 (1989).
Onaivi, E. et al., "Chronic Nicotine Reverses Age-Associated Increases in Tail-Flick Latency and Anxiety in Rats", Life Sciences, vol. 54, pp. 193-202 (1994).
Perry E., "The Cholinergic Hypothesis-Ten Years On", British Medical Bulletin, vol. 42, pp. 63-69 (1986).
Pomponi, M. et al., "Present state and future development of the therapy of Alzheimer disease", Aging, vol. 2(2), pp. 125-153 (1990).
Rapier, C. et al., "Stereoselective Nicotine-Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation", Journal of Neurochemistry, vol. 50, pp. 1123-1130 (1988).
Rinne, J. et al., "A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease", Brain Research, vol. 547, pp. 167-170 (1991).
Rowell, P., "Current Concepts on the Effects of Nicotine on Neurotransmitter Release in the Central Nervous System", Adv. Behav. Biol., vol. 31, pp. 191-208 (1987). Release form Mouse Cerebral Cortical Synaptosomes", Journal of Neurochemistry, vol. 43, pp. 1593-1598 (1984).
Sahakian, B. et al., "The Effects of Nicotine on Attention, Information Processing, and Short-Term Memory in Patients with Dementia of the Alzheimer Type", British Journal of Psychiatry, vol. 154, pp. 797-800 (1989).
Sanberg, P. et al., "Nicotine Potentiation of Haloperidol-Induced Catalepsy: Striatal Mechanisms", Pharmacology Biochemistry and Behavior, vol. 46, pp. 303-307 (1993).
Sandor, N. et al., "Effect of nicotine on dopaminergic-cholinergic interaction in the striatum", Brain Research, vol. 567, pp. 313-316 (1991).
Sherwood, Human Psychopharm., vol. 8, pp. 155-184 (1993).
Sjak-Shie, N. et al., "Effects of chronic nicotine and pilocarpine in nucleus basalis lesioned rats", Brain Research, vol. 624, pp. 295-298 (1993).
Smith, C. et al., "Nicotine, Parkinson's and Alzheimer's Disease", Rev. in Neuroscience, vol. 3, pp. 25-43 (1992).
Toth, E. et al., "Effect of Nicotine on Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions: Role of Glutamic Acid", Neurochemical Research, vol. 17(3), pp. 265-271 (1992).
van Duijan, C. et al., "Relation between nicotine intake and Alzheimer's disease", BMJ, vol. 302, pp. 1491-1494 (1991).
Vizi, E., "Acetylcholine release from guinea-pig ileum by parasympathetic ganglion stimulants and gastrin-like polypeptides", British Journal Pharmacology, vol. 47, pp. 765-777 (1973).
Physicians' Desk Reference, 48 Edition, pp. 899-903 (1994), "Sinemet".
Physicians' Desk Reference, 48 Edition, pp. 2067-2069 (1994), "Parlodel".
Physicians' Desk Reference, 48 Edition, pp. 2309-2311 (1994), "Eldepryl".
Hodges, H. et al., "Nicotine as a Tool to Characterize the Role of the Forebrain Cholinergic Projection System in Cognition", Biology of Nicotine, pp. 157-182(1991).
Pomerleau, et al., "The Effects of Cigarette Smoking on Pain and Anxiety", Addictive Behavi 9, pp. 265-271 (1984).
Wagner, et al., "Does Smoking Reduce the Risk of Neuroleptic Parkinsonoids?", Pharmacopsychiatry, vol. 21, pp. 302-303 (1988).
Baron, J. "Proceedings from Intl. Symp. Nic.", S42 (1994).
Janson, A. et al., "Proceedings from Intl. Symp. Nic.", S43 (1994).
Levin, E. et al., "Proceedings from Intl. Symp. Nic.", S44 (1994).
Joseph M. et al., "Proceedings from Intl. Symp. Nic.", S45 (1994).
Newhouse, P. et al., "Proceedings from Intl. Symp. Nic.", S46 (1994).
Bencherif Merouane
Caldwell William Scott
Dull Gary Maurice
Lippiello Patrick Michael
LandOfFree
Pharmaceutical compositions for prevention and treatment of cent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions for prevention and treatment of cent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions for prevention and treatment of cent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-244720